Drug Screening Assays, Antitumor

"Drug Screening Assays, Antitumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.

Descriptor ID	D004354
MeSH Number(s)	E01.370.225.500.388 E05.200.500.388 E05.242.417 E05.337.550.200
Concept/Terms	Drug Screening Assays, Antitumor Drug Screening Assays, Antitumor Antitumor Drug Screening Assays Cancer Drug Tests Cancer Drug Test Drug Test, Cancer Drug Tests, Cancer Test, Cancer Drug Tests, Cancer Drug Drug Screening Tests, Tumor-Specific Drug Screening Tests, Tumor Specific Antitumor Drug Screens Antitumor Drug Screen Drug Screen, Antitumor Drug Screens, Antitumor Screen, Antitumor Drug Screens, Antitumor Drug Anti-Cancer Drug Screens Anti Cancer Drug Screens Anti-Cancer Drug Screen Drug Screen, Anti-Cancer Drug Screens, Anti-Cancer Screen, Anti-Cancer Drug Screens, Anti-Cancer Drug Anticancer Drug Sensitivity Tests Tumor-Specific Drug Screening Tests Tumor Specific Drug Screening Tests Dye Exclusion Assays, Antitumor Dye Exclusion Assays, Antitumor

Below are MeSH descriptors whose meaning is more general than "Drug Screening Assays, Antitumor".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Diagnosis [E01]
Diagnostic Techniques and Procedures [E01.370]
Clinical Laboratory Techniques [E01.370.225]
Cytological Techniques [E01.370.225.500]
Drug Screening Assays, Antitumor [E01.370.225.500.388]
Investigative Techniques [E05]
Clinical Laboratory Techniques [E05.200]
Cytological Techniques [E05.200.500]
Drug Screening Assays, Antitumor [E05.200.500.388]
Cytological Techniques [E05.242]
Drug Screening Assays, Antitumor [E05.242.417]
Evaluation Studies as Topic [E05.337]
Drug Evaluation, Preclinical [E05.337.550]
Drug Screening Assays, Antitumor [E05.337.550.200]

Below are MeSH descriptors whose meaning is more specific than "Drug Screening Assays, Antitumor".

Drug Screening Assays, Antitumor
Tumor Stem Cell Assay

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Screening Assays, Antitumor" by people in this website by year, and whether "Drug Screening Assays, Antitumor" was a major or minor topic of these publications.

Bar chart showing 114 publications over 26 distinct years, with a maximum of 10 publications in 2010 and 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	0	1	1
2000	0	2	2
2002	0	1	1
2003	0	2	2
2004	0	2	2
2005	0	2	2
2006	1	0	1
2007	1	4	5
2008	0	3	3
2009	1	4	5
2010	1	9	10
2011	0	6	6
2012	0	2	2
2013	0	5	5
2014	2	8	10
2015	0	7	7
2016	1	5	6
2017	0	8	8
2018	1	3	4
2019	1	5	6
2020	0	6	6
2021	0	7	7
2022	0	5	5
2023	0	1	1
2024	1	1	2
2025	0	5	5

Below are the most recent publications written about "Drug Screening Assays, Antitumor" by people in Profiles.

Mondal T, Sahoo P, Nandi SK, Kundu S, Li M, Haldar N, Kabir R, Mitra K, Roy S, Das M, Ghosh CK. Opto-magnetic optimization enhances the multimodal therapeutic and diagnostic (UCL/T1-T2W MRI) potential of GdOF against MDA-MB-231. J Mater Chem B. 2025 Aug 13; 13(32):9993-10008.

View in: PubMed
Acosta-Mercado J, Oliveras-Alsina A, Marcano-Maiz AI, Rivera-Torres AP, Cordero-Gimenez KT, Malavez-Cajigas S, Bayro MJ, Ramos-Benitez MJ, Pi?ero Cruz DM. Evaluating Naphthalene-Modified Metallosalen Complexes as Anticancer Agents. J Med Chem. 2025 Jul 24; 68(14):14300-14311.

View in: PubMed
Okpattah D, Karki A, Pillarsetty NVK, Harding WW. Synthesis and evaluation of aporphinoid 5-HT7AR ligands as inhibitors of PC3 prostate cancer cell growth. Bioorg Med Chem Lett. 2025 Dec 01; 128:130328.

View in: PubMed
Mihaylova V, Iliev I, Vasileva A, Mazzio E, Mochona B, Mateeva N, Tasheva D. Synthesis and Evaluation of the Antiproliferative Activity of the Derivatives of 3,5-Diaryl-3,4-dihydro-2H-pyrrole-2-carboxylic Acids. Molecules. 2025 Apr 03; 30(7).

View in: PubMed
Ruidas B, Choudhury N, Chaudhury SS, Sur TK, Bhowmick S, Saha A, Das P, De P, Das Mukhopadhyay C. Precision targeting of fat metabolism in triple negative breast cancer with a biotinylated copolymer. J Mater Chem B. 2025 01 22; 13(4):1363-1371.

View in: PubMed
El-Bayaa MN, Kotb ER, Messaoudi S, Awad HM, Saleh MG, Soliman HA. Synthesis, anticancer activity, docking and computational studies of new pyridyl-glycosyl hybrids and acyclic analogs. Future Med Chem. 2024; 16(20):2119-2133.

View in: PubMed
Liu W, Mousa AAK, Hopkins AM, Wu YF, Thu KL, Campbell M, Lees SJ, Ramachandran R, Hou J. Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer. ChemMedChem. 2024 Aug 19; 19(16):e202400013.

View in: PubMed
Swain RM, Sanchez A, Gutierrez DA, Varela-Ramirez A, Aguilera RJ. Thiophene derivative inflicts cytotoxicity via an intrinsic apoptotic pathway on human acute lymphoblastic leukemia cells. PLoS One. 2023; 18(12):e0295441.

View in: PubMed
Yin H, Chen Y, Zhong Q, Zheng S, Wang G, He L. Design, synthesis, and antitumor study of a series of novel 1-Oxa-4-azaspironenone derivatives. Bioorg Med Chem Lett. 2022 10 15; 74:128925.

View in: PubMed
Jia J, Yin H, Chen C, Hu M, Zhong Q, Zheng S, Zhang W, Li H, Xu L, Wang G, He L. Design, synthesis, and evaluation of a novel series of mono-indolylbenzoquinones derivatives for the potential treatment of breast cancer. Eur J Med Chem. 2022 Jul 05; 237:114375.

View in: PubMed

People

Explore

Similar Concepts

Top Journals